1. Home
  2. ACU vs GLSI Comparison

ACU vs GLSI Comparison

Compare ACU & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACU
  • GLSI
  • Stock Information
  • Founded
  • ACU 1867
  • GLSI 2006
  • Country
  • ACU United States
  • GLSI United States
  • Employees
  • ACU N/A
  • GLSI N/A
  • Industry
  • ACU Industrial Machinery/Components
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACU Consumer Discretionary
  • GLSI Health Care
  • Exchange
  • ACU Nasdaq
  • GLSI Nasdaq
  • Market Cap
  • ACU 145.9M
  • GLSI 134.6M
  • IPO Year
  • ACU N/A
  • GLSI 2020
  • Fundamental
  • Price
  • ACU $42.81
  • GLSI $11.48
  • Analyst Decision
  • ACU
  • GLSI Strong Buy
  • Analyst Count
  • ACU 0
  • GLSI 1
  • Target Price
  • ACU N/A
  • GLSI $39.00
  • AVG Volume (30 Days)
  • ACU 8.1K
  • GLSI 43.7K
  • Earning Date
  • ACU 10-17-2025
  • GLSI 08-14-2025
  • Dividend Yield
  • ACU 1.49%
  • GLSI N/A
  • EPS Growth
  • ACU N/A
  • GLSI N/A
  • EPS
  • ACU 2.55
  • GLSI N/A
  • Revenue
  • ACU $194,061,991.00
  • GLSI N/A
  • Revenue This Year
  • ACU $4.69
  • GLSI N/A
  • Revenue Next Year
  • ACU $6.15
  • GLSI N/A
  • P/E Ratio
  • ACU $16.92
  • GLSI N/A
  • Revenue Growth
  • ACU 0.70
  • GLSI N/A
  • 52 Week Low
  • ACU $34.35
  • GLSI $8.06
  • 52 Week High
  • ACU $45.42
  • GLSI $16.50
  • Technical
  • Relative Strength Index (RSI)
  • ACU 54.97
  • GLSI 48.08
  • Support Level
  • ACU $40.51
  • GLSI $11.35
  • Resistance Level
  • ACU $43.44
  • GLSI $12.07
  • Average True Range (ATR)
  • ACU 1.62
  • GLSI 0.57
  • MACD
  • ACU 0.14
  • GLSI -0.12
  • Stochastic Oscillator
  • ACU 68.81
  • GLSI 8.78

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: